Targeting B Lymphocytes as Therapy for ANCA-Associated Vasculitis

Rheumatic Disease Clinics of North America

Volumn 33, Issue 4, 2007, Pages 741-754

  Golbin, Jason M ^a   Specks, Ulrich ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CD20 ANTIBODY; CYCLOPHOSPHAMIDE; EPRATUZUMAB; GLUCOCORTICOID; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISONE; RAPAMYCIN; RITUXIMAB;

B LYMPHOCYTE; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; DRUG TARGETING; HUMAN; LYMPHOCYTE DEPLETION; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; VASCULITIS; VIRUS REACTIVATION; WEGENER GRANULOMATOSIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; CHURG-STRAUSS SYNDROME; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 36248952098     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2007.09.001     Document Type: Review

References (74)

1. Jennette J.C., Falk R.J., Andrassy K., et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 37 2 (1994) 187-192
2. Jayne D., Rasmussen N., Andrassy K., et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349 1 (2003) 36-44
3. De Groot K., Rasmussen N., Bacon P.A., et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52 8 (2005) 2461-2469
4. Jayne D.R., Gaskin G., Rasmussen N., et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 18 7 (2007) 2180-2188
5. Guillevin L., Durand-Gasselin B., Cevallos R., et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 42 3 (1999) 421-430
6. Keogh K.A., and Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med 115 4 (2003) 284-290
7. Finkielman J.D., Lee A.S., Hummel A.M., et al. ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis. Am J Med 120 7 (2007) 643
8. Hoffman G.S., and Specks U. Anti-neutrophil cytoplasmic antibodies. Arthritis Rheum 41 (1998) 1521-1537
9. Walton E.W. Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). Br Med J 2 (1958) 265-270
10. Fauci A.S., Haynes B.F., Katz P., et al. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 98 (1983) 76-85
11. Hoffman G.S., Kerr G.S., Leavitt R.Y., et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 116 (1992) 488-498
12. Talar-Williams C., Hijazi Y.M., Walther M.M., et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 124 (1996) 477-484
13. Sneller M.C., Hoffman G.W., Talar-Williams C., et al. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 38 (1995) 608-613
14. Langford C.A., Talar-Williams C., Barron K.S., et al. A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 42 12 (1999) 2666-2673
15. Grillo-Lopez A.J., White C.A., Dallaire B.K., et al. Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. Curr Pharm Biotechnol 1 1 (2000) 1-9
16. Einfeld D.A., Brown J.P., Valentine M.A., et al. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 7 3 (1988) 711-717
17. Tedder T.F., and Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 15 9 (1994) 450-454
18. Silverman G.J., and Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 48 6 (2003) 1484-1492
19. Demidem A., Lam T., Alas S., et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 12 3 (1997) 177-186
20. Golay J., Zaffaroni L., Vaccari T., et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 95 12 (2000) 3900-3908
21. Shan D., Ledbetter J.A., and Press O.W. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 48 12 (2000) 673-683
22. Johnson P., and Glennie M. The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol 30 1 Suppl 2 (2003) 3-8
23. Uchida J., Hamaguchi Y., Oliver J.A., et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 199 12 (2004) 1659-1669
24. Eisenberg R., and Looney R.J. The therapeutic potential of anti-CD20: "what do B-cells do?". Clin Immunol 117 3 (2005) 207-213
25. Anolik J.H., Barnard J., Cappione A., et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 50 11 (2004) 3580-3590
26. Keogh K.A., Ytterberg S.R., Fervenza F.C., et al. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 173 2 (2006) 180-187
27. Roll P., Palanichamy A., Kneitz C., et al. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 54 8 (2006) 2377-2386
28. Anolik J.H., Barnard J., Owen T., et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 56 9 (2007) 3044-3056
29. Gonzalez-Stawinski G.V., Yu P.B., Love S.D., et al. Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab). Clin Immunol 98 2 (2001) 175-179
30. van der Kolk L.E., Baars J.W., Prins M.H., et al. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 100 6 (2002) 2257-2259
31. Browning J.L. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov 5 7 (2006) 564-576
32. McLaughlin P., Grillo-Lopez A.J., Link B.K., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16 8 (1998) 2825-2833
33. Salama A.D., and Pusey C.D. Drug insight: rituximab in renal disease and transplantation. Nat Clin Pract Nephrol 2 4 (2006) 221-230
34. Protheroe A., Edwards J.C., Simmons A., et al. Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma. Rheumatology (Oxford) 38 11 (1999) 1150-1152
35. Specks U., Fervenza F.C., McDonald T.J., et al. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 44 12 (2001) 2836-2840
36. Keogh K.A., Wylam M.E., Stone J.H., et al. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52 1 (2005) 262-268
37. Wung P.K., Holbrook J.T., Hoffman G.S., et al. Herpes zoster in immunocompromised patients: incidence, timing, and risk factors. Am J Med 118 12 (2005) 1416
38. Erikkson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 257 (2005) 540-548
39. Gottenberg J.E., Guillevin L., Lambotte O., et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 64 6 (2005) 913-920
40. Omdal R., Wildhagen K., Hansen T., et al. Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response. Scand J Rheumatol 34 3 (2005) 229-232
41. Ferraro A.J., Day C.J., Drayson M.T., et al. Effective therapeutic use of rituximab in refractory Wegener's granulomatosis. Nephrol Dial Transplant 20 3 (2005) 622-665
42. Cheung C.M., Murray P.I., and Savage C.O. Successful treatment of Wegener's granulomatosis associated scleritis with rituximab. Br J Ophthalmol 89 11 (2005) 1542
43. Memet B., Rudinskaya A., Krebs T., et al. Wegener granulomatosis with massive intracerebral hemorrhage: remission of disease in response to rituximab. J Clin Rheumatol 11 6 (2005) 314-318
44. Maher L.V., and Wilson J.G. Successful treatment of rheumatoid vasculitis-associated foot drop with rituximab. Rheumatology (Oxford) 45 11 (2006) 1450-1451
45. Tamura N., Matsudaira R., Hirashima M., et al. Two cases of refractory Wegener's granulomatosis successfully treated with rituximab. Intern Med 46 7 (2007) 409-414
46. Aries P.M., Hellmich B., Voswinkel J., et al. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 65 7 (2006) 853-858
47. Brihaye B., Aouba A., Pagnoux C., et al. Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients. Clin Exp Rheumatol 25 1 Suppl 44 (2007) S23-S27
48. Flores-Suarez L. Rituximab is useful in Wegener granulomatosis patients with predominant granulomatous disease. Clin Exp Rheumatol 25 1 Suppl 44 (2007) S113
49. Seo P., Specks U., and Keogh K.A. Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations. Clin Exp Rheumatol 25 1 Suppl 44 (2007) S111
50. Sanchez-Cano D., Callejas-Rubio J.L., Rios-Fernandez R., et al. Use of rituximab in Wegener's granulomatosis: comment on the article by Wong. Nephrol Dial Transplant 22 3 (2007) 958-959 [author reply: 959]
51. Stasi R., Pagano A., Stipa E., et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 98 4 (2001) 952-957
52. Smith K.G., Jones R.B., Burns S.M., et al. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 54 9 (2006) 2970-2982
53. Golbin J.M., Keogh K.A., Fervenza F.C., et al. Update on rituximab use in patients with chronically relapsing Wegener's granulomatosis. Clin Exp Rheumatol 25 1 Suppl 44 (2007) S111
54. Henes J.C., Fritz J., Koch S., et al. Rituximab for treatment-resistant extensive Wegener's granulomatosis: additive effects of a maintenance treatment with leflunomide. Clin Rheumatol (2007) in press
55. Kaushik V.V., Reddy H.V., and Bucknall R.C. Successful use of rituximab in a patient with recalcitrant Churg-Strauss syndrome. Ann Rheum Dis 65 8 (2006) 1116-1117
56. Koukoulaki M., Smith K.G., and Jayne D.R. Rituximab in Churg-Strauss syndrome. Ann Rheum Dis 65 4 (2006) 557-559
57. Dai M.S., Chao T.Y., Kao W.Y., et al. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol 83 12 (2004) 769-774
58. Tsutsumi Y., Kawamura T., Saitoh S., et al. Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy. Leuk Lymphoma 45 3 (2004) 627-629
59. Freim Wahl S.G., Folvik M.R., and Torp S.H. Progressive multifocal leukoencephalopathy in a lymphoma patient with complete remission after treatment with cytostatics and rituximab: case report and review of the literature. Clin Neuropathol 26 2 (2007) 68-73
60. Garcia-Suarez J., de Miguel D., Krsnik I., et al. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies. Am J Hematol 80 4 (2005) 271-281
61. Mackay F., Schneider P., Rennert P., et al. BAFF and APRIL: a tutorial on B cell survival. Annu Rev Immunol 21 (2003) 231-264
62. Baker K.P. BLyS-an essential survival factor for B cells: basic biology, links to pathology and therapeutic target. Autoimmun Rev 3 5 (2004) 368-375
63. Cheema G.S., Roschke V., Hilbert D.M., et al. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 44 6 (2001) 1313-1319
64. Mariette X., Roux S., Zhang J., et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 62 2 (2003) 168-171
65. Krumbholz M., Specks U., Wick M., et al. BAFF is elevated in serum of patients with Wegener's granulomatosis. J Autoimmun 25 4 (2005) 298-302
66. Stohl W., and Looney R.J. B cell depletion therapy in systemic rheumatic diseases: different strokes for different folks?. Clin Immunol 121 1 (2006) 1-12
67. Lesley R., Xu Y., Kalled S.L., et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 20 4 (2004) 441-453
68. Cambridge G., Stohl W., Leandro M.J., et al. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 54 3 (2006) 723-732
69. Pers J.O., Devauchelle V., Daridon C., et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjogren's syndrome. Arthritis Rheum 56 5 (2007) 1464-1477
70. Leonard J.P., Coleman M., Ketas J.C., et al. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin Cancer Res 10 16 (2004) 5327-5334
71. Leonard J.P., Coleman M., Ketas J., et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 23 22 (2005) 5044-5051
72. Steinfeld S.D., Tant L., Burmester G.R., et al. Epratuzumab (humanized anti-CD22 antibody) in primary Sjogren's syndrome: an open-label phase I/II study. Arthritis Res Ther 8 4 (2006) R129
73. Dorner T., Kaufmann J., Wegener W.A., et al. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 8 3 (2006) R74
74. Carnahan J., Stein R., Qu Z., et al. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol 44 6 (2007) 1331-1341